Mobile

A double blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, tolerability and immunogenicity of repeated s.c administrations of 100µg NIC002 vaccine in cigarette smokers wh...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-006741-40

A double blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, tolerability and immunogenicity of repeated s.c administrations of 100µg NIC002 vaccine in cigarette smokers who are motivated to quit smoking

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To test the hypothesis that treatment with NIC002 increases the 4-week rate of continuous abstinence from smoking between weeks 8 and 12 inclusive compared with placebo

Critère d'inclusion

  • smokers

Liens